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Abstract  
Introduction 
Single disease state led evidence-based guidelines do not provide sufficient coverage of 
issues of multimorbidities, with the cumulative impact of recommendations often resulting in 
overwhelming medicines burden. Inappropriate polypharmacy increases the likelihood of 
adverse drug events, drug interactions and non-adherence.  
Areas covered 
A detailed description of a pan-European initiative, ‘Stimulating Innovation Management of 
Polypharmacy and Adherence in the Elderly, SIMPATHY’, which is a project funded by the 
European Commission to support innovation across the European Union. This includes a 
systematic review of the literature aiming to summarise and review critically current policies 
and guidelines on polypharmacy management in older people. The policy driven, evidence-
based approach to managing inappropriate polypharmacy in Scotland is described, with 
consideration of a change management strategy based on Kotter’s eight step process for 
leading sustainable change. 
Expert opinion 
The challenges around promoting appropriate polypharmacy are on many levels, primarily 
clinical, organisational and political, all of which any workable solution will need to address. 
To be effective, safe and efficient, any programme that attempts to deal with the complexities 
of prescribing in this population must be patient-centred, clinically robust, multidisciplinary 
and designed to fit into the healthcare system in which it is delivered.   
 
Keywords 
aged, inappropriate prescribing, literature review, organisational change, polypharmacy, 
SIMPATHY  
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1. Introduction  
1.1 Multimorbidity  
Multimorbidity is defined by the World Health Organisation as ‘the co-occurrence of two or 
more chronic medical conditions in one person’ [1]. Epidemiological data indicate that 
multimorbidity increases markedly with age, being prevalent in almost two thirds of 
individuals aged 80 years and over [2,3]. On average, those with multimorbidities have at 
least three long-term conditions, with cardiovascular (87.7 % of individuals), metabolic (62.2 
%) and rheumatoid (40.2%) being the three most common. There is a significant relationship 
between multimorbidities and the use of health services; multimorbidity is related positively 
to interaction with community based health services (twice as high as non-multimorbid), and 
hospitalisation (three times higher) [4]. Multimorbidities impact quality of life, being 
associated with multiple symptoms, disabilities such as cognitive impairments, limited 
activities of daily living and reduced mobility hence are major public health issues [5]. One 
consequence is high economic burden due to complex healthcare needs and frequent 
interaction with healthcare services [6].  
 
1.2 Polypharmacy  
While the United Nations (UN) refers to those aged 60 years and over as ‘older people’, most 
developed countries have accepted the chronological age of 65 years as the definition of an 
‘older person’ [7]. Given advances in pharmacotherapy, older people are likely to be 
prescribed multiple medicines to manage their multimorbidities. Single disease state led 
evidence-based guidelines do not provide sufficient coverage of issues of multimorbidities or 
the effects of old age, with the cumulative impact of treatment recommendations often 
resulting in overwhelming medicines burden [8,9]. Furthermore, as life expectancy increases, 
not only will people take medicines for a longer period of time but may develop more 
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conditions that have the potential to need treatment but for which there is limited evidence of 
efficacy in extremes of age.  
 
There is a wealth of recent evidence on the prevalence of prescribing of multiple medicines in 
older people. Data originating in the United Kingdom (UK), published in 2014, highlighted 
that 20.8% of those with two clinical conditions were prescribed four to nine medicines, and 
10.1% of patients ten or more medicines; in patients with six or more comorbidities, values 
were 47.7% and 41.7% respectively and these figures increase with age [10]. A recent 
analysis of prescribing trends in the United States (USA) found that, between 1999 and 2012, 
polypharmacy (defined as ≥ 5 prescription medicines) increased from 24% to 39% for those 
aged 65 and above [11]. While there may be variability across countries, a narrative literature 
review published in 2005 identified this is a widespread global issue [12].  
 
Polypharmacy, the prescribing of multiple medicines, is considered to be ‘one of the greatest 
prescribing challenges’, increasing the likelihood of adverse drug events, drug interactions 
and contributing to non-adherence to medicines regimens [13]. Furthermore, polypharmacy 
impacts significantly health outcomes and healthcare resources. While traditionally 
polypharmacy has been classified in terms of the number of medicines (usually defined as the 
use of five or more medicines) [14], Patterson et al. suggested, as part of a Cochrane review 
in 2012 (later updated in 2014), that there should be a change in emphasis from 
‘inappropriate polypharmacy’ (prescribing of multiple medicines which are either 
inappropriate or no longer indicated) to ‘appropriate’ or ‘optimal polypharmacy’ (appropriate 
prescribing of multiple medicines) [15-17].  
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1.3 Managing inappropriate polypharmacy 
It is evident that inappropriate polypharmacy is a major concern, hence promoting 
appropriate polypharmacy at the point of medicines initiation or during medicines review is, 
therefore, of the utmost importance and deserves greater attention.  
 
A systematic review reported by Patterson et al. aimed to determine which interventions, 
alone, or in combination, were effective in improving appropriate polypharmacy and 
reducing medicines-related problems in older people. The review findings were based upon 
ten papers, with the authors concluding that, while there is uncertainty about the elements of 
intervention that impact positively appropriate polypharmacy, pharmaceutical care appears to 
improve prescribing [16,17]. 
 
There are a number of tools which may assist in promoting appropriate prescribing in older 
people. A systematic review by Kaufmann et al. aimed to create a comprehensive and 
structured overview of existing tools to assess potentially inappropriate prescribing [18]. 
Findings identified 46 different tools, with variation in methodological aspects and a general 
lack of validation in clinical settings. While many might serve as useful aids to improve 
prescribing, each tool has its limitations, strengths and weaknesses, and most were specific to 
the region and context in which they were developed. These tools were categorised as 
explicit, implicit or mixed. While implicit criteria focus on clinician interpretation and are 
time consuming, explicit criteria are designed to be easily and effectively interpreted. They 
provide details of categories of medicines and associated prescribing indicators to enhance 
reliable treatment evaluation. The most widely used include Beers Criteria, STOPP-START 
and Laroche Criteria [19-21]. The authors concluded that this review could serve as a 
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summary to assist readers in choosing a tool, either for research purposes or for daily practice 
[18]. 
 
There remains, however, the need to translate the research evidence to policies and guidance 
for practitioners managing inappropriate polypharmacy and promoting appropriate 
polypharmacy. Developing, implementing and sustaining change requires commitment and 
investment at all levels of healthcare systems. The emphasis of the remainder of this paper is 
on a detailed description of a pan-European initiative, with emphasis on the policy driven 
management of inappropriate polypharmacy in Scotland.  
 
2. Stimulating Innovation Management of Polypharmacy and Adherence in the Elderly,  
SIMPATHY  
2.1 SIMPATHY 
Stimulating Innovation Management of Polypharmacy and Adherence in the Elderly 
(SIMPATHY) is a project funded by the European Union’s Health Programme (2014-2020) 
[22], which commenced in June 2015 and will be complete by summer of 2017. 
Polypharmacy is the primary focus, with a secondary related focus on patient non-adherence 
to medicines. The SIMPATHY consortium comprises: healthcare policymakers; practising 
physicians; pharmacists; health economists; professionals responsible for large data base 
evaluation; and leading academic researchers, as shown in Figure 1, representing ten 
institutions in eight European countries.  
 
<INSERT FIGURE 1 HERE> 
 
The project target stakeholders are those who can provide valuable and complementary 
contributions in tackling inappropriate polypharmacy in older people, namely: politicians; 
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policymakers; healthcare commissioners; healthcare providers; professional bodies and 
regulators; educators; and patient representatives.  
 
2.2 SIMPATHY aim and work programme 
The overarching aim of SIMPATHY is to stimulate and support innovation across the EU in 
the management of polypharmacy and adherence in the elderly, with specific focus on 
addressing inappropriate polypharmacy. There is much emphasis on translating evidence to 
practice impacting healthcare structures, processes and patient outcomes (clinical, humanistic 
and economic). The consortium programme of work will provide case studies in a range of 
different environments, identifying the framework and politico-economic basis for an EU-
wide benchmarking exercise. Furthermore, the development of contextualised change 
management approaches and tools will aid target stakeholders who can influence and 
implement the necessary changes. Carefully targeted and comprehensive dissemination and 
engagement activities will be deployed to stimulate and support the innovation necessary to 
address this major EU healthcare challenge.  
 
Work streams comprise: a systematic review of the published and grey literature of identified 
policies and guidelines across the EU for promoting appropriate polypharmacy in older 
people; case studies of the management of polypharmacy in the consortium countries; a 
benchmarking survey, aiming to collect quantitative and qualitative data from across the EU 
to provide a picture of progress towards addressing the urgent challenges associated with 
polypharmacy; a Political, Economic, Sociocultural, Technological, Environmental and Legal 
(PESTEL) analysis [23] and analysis of the Strengths, Weaknesses, Opportunities and 
Threats (SWOT) relating to polypharmacy and adherence management in the consortium 
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countries; and, validation of SIMPATHY findings through an EU-wide consensus (modified 
Delphi) study.  
 
The remainder of this paper focuses on the evidence derived from the literature review, the 
approach employed around change management and the case studies. 
 
 
3. Literature review 
3.1 Aim 
Several published systematic literature reviews have focused on aspects of polypharmacy 
management [15-17], but with little emphasis on grey literature, notably policies and 
guidelines. The aim of this review was to summarise and review critically current policies 
and guidelines on polypharmacy management in older people (publications dated: 01 January 
2010 – 30 June 2015).  
 
3.2 Methods 
A comprehensive, multifaceted search strategy was devised to target publications outlining 
strategic guidance for addressing inappropriate polypharmacy (but not implementation of 
guidance) in clinical practice, healthcare systems or research.  
To be included, at least one major stated purpose had to be the development of policies or 
guidelines to improve at least one component of polypharmacy management in older people 
and had to specify explicitly the guidance. Publications that only made recommendations as a 
part of the conclusions were excluded.  
There were several methods employed for the search, including a targeted database search, 
online grey literature search, desk review, and contact with key stakeholders. 
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A database search was conducted on Medline (via PubMed), Embase, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL) and The Cochrane Library, according to 
PRISMA-P 2015 guidelines [24]. Comprehensive search strings were developed, for example 
for Medline: (multimedic*[ti] OR “multiple medication"[ti] OR polifarma*[ti] OR 
polyfarma*[ti] OR polimedicin*[ti] OR polymedicin*[ti] OR polipharma*[ti] OR 
polypharma*[ti] OR polipragma*[ti] OR polypragma*[ti] OR politerap* [ti] OR polyterap* 
[ti]) AND (elder* [ti] OR old* [ti] OR age* [ti] OR geriatric*[ti]) 
 
An online search of the grey literature of policies and guidelines was performed in ten 
European countries (Germany, Greece, Italy, Northern Ireland, Poland, Portugal, Spain, 
Sweden, The Netherlands and Scotland). The search strategy included all 24 combinations of 
keywords from the following two groups, 
 
Group 1: multimedication, multiple medication, polymedicine, polypharmacy, polypragmasy, 
polytherapy 
Group 2: aged, elder, geriatric, old 
 
After translating for each country, and cross-checking that these translated keywords were 
applicable to the management of polypharmacy, a search was performed using the Google 
search engine. The country-specific search was restricted to the relevant country domain (i.e. 
.de for Germany, .gr for Greece, etc.). In order to allow for comparable results to be obtained, 
and avoid the effect of cookie files, the previous search history was disabled, and the 
‘private’ or ‘incognito’ mode of the search enabled (wherever applicable). For each 
combination of keywords, the first ten results generated by the Google search (giving a total 
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of 240) was registered in a dedicated spreadsheet, and analysed for each of the search based 
countries.  
 
The search was complemented with any guidance documents known to the SIMPATHY 
consortium, as well as those identified through targeted contact with local stakeholders (two 
physicians, two pharmacists, and one politician) in each country. Guidance documents were 
entered into a dedicated spreadsheet and screened to remove duplicate. Titles and abstracts of 
each item were reviewed independently by two reviewers in each country who were fluent in 
the relevant language. Final eligibility to be included in the review was determined by 
screening of full texts. 
 
Data extracted from relevant guidance documents were entered into a dedicated spreadsheet 
and quality rated using the AGREE II instrument (The Appraisal of Guidelines for REsearch 
& Evaluation ) which has 23 items organised into domains of: scope and purpose; stakeholder 
involvement; rigour of development; clarity of presentation; applicability; and editorial 
independence [25]. Each item was scored independently on a seven-point scale by two 
individuals educated to doctoral level and with expertise in the field of polypharmacy. A 
score of one indicated an absence of information or that the concept was reported very 
poorly. A score of seven indicated that the quality of reporting was exceptional and all 
criteria were met. A score between two and six indicated that the reporting of the AGREE II 
item did not fully meet the criteria. The overall score is the median of the 23 item scores.  
 
To broaden the search beyond the consortium countries, the search was also conducted in the 
US Agency for Healthcare Research and Quality National Guidelines Clearinghouse and also 
the Guidelines International Network [26,27]. 
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3.3 Results 
There were 444 hits, of which 214 duplicates were removed, 136 were excluded for not 
dealing with polypharmacy management in older people, and 11 for other reasons (e.g. type 
of publication such as opinion, case report). The full text review of 83 papers revealed only 
one which fulfilled the eligibility criteria.  
 
The number of keyword combinations varied between countries, with a range of 3-24 due to 
issues in translation of keywords and applicability to the local literature on polypharmacy 
management. Furthermore, the Google search did not always retrieve the target number of 
ten. The total number of Google search results assessed against the eligibility criteria was 
1705. Of these, 807 were excluded for not focusing on polypharmacy management in older 
people and 810 for other reasons, usually not providing guidance. The full text of 88 items 
was reviewed, with ten fulfilling all criteria to be retained in the review. Full details are 
provided in Table 1.  
 
<INSERT Table 1 HERE> 
 
 
An additional 14 guidance documents were identified, as shown in Table 2.  
 
<INSERT Table 2 HERE> 
 
Combining the guidance documents derived from all sources and removing duplicates gave a 
final total of 19 documents from five countries, as listed in Table 3, which also highlights 
quality according to the AGREE II-GRS criteria. The median overall score was 5, with a 
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range of 3-7; three documents scored the maximum of seven, originating from Scotland, 
Germany and The Netherlands. 
 
<INSERT Table 3 HERE> 
 
 
The comprehensive and quality assured approaches employed in this literature review 
identified that only five EU countries had produced guidance documents which focus 
specifically on polypharmacy management in older people. In addition, only three of these 
were found to be fully satisfactory in terms of the AGREE II criteria. Most of the identified 
guidance documents targeted both polypharmacy in older people and also other groups of 
vulnerable people. All but one was generic (not specific to any single medical condition). 
Most paid attention to medicines selection at the point of prescribing (e.g. avoiding certain 
high-risk medicines, dose adjustment, and a ‘start low and go slow’ approach), and the need 
for regular review of medicines. Physicians and pharmacists were identified as key players, 
with a focus on multidisciplinary care and team working. Only seven guidance documents 
had any coverage of issues of non-adherence to medicines in older people.  
 
The wider search identified further guidance documents from Australia [47-49], the US 
[50,51], and New Zealand [52].  
 
Despite the comprehensive search and quality assurance approaches, there are several 
limitations to this review hence the findings should be interpreted with some caution. Grey 
literature searches are always limited in terms of retrieving all relevant literature. The search 
was restricted to Google and while this is the most widely used search engine, it is possible 
that not all guidance and policies were captured. In addition, it is highly likely that less 
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widely used or disseminated policies and guidelines, such as those operating at local levels, 
were not retrieved. It is therefore important that those developing and implementing strategic 
approaches to the management of polypharmacy in older people disseminate widely.  
 
The Scottish polypharmacy guidance was identified as one of the documents that scored the 
highest score of the AGREE II criteria [29], hence is described in greater detail, with 
emphasis on the evidence used to derive the guidance.  
 
 
3.4. Policy driven approach to management of inappropriate polypharmacy in Scotland 
Like many areas in the developed world, Scotland has had to face the challenge of providing 
healthcare to an ageing population. From 2006 - 31 there is a 62% projected rise in those 
aged 65 years and older, a 144% projected rise in those aged 85 years and older, and a 
projected increased prevalence of long-term conditions, notably chronic obstructive 
pulmonary disease and diabetes mellitus [53]. Figure 2 provides analysis of Scottish data 
relating to number of medicines dispensed in the community by age band, highlighting the 
increasing trend of positive relationship between age and number of prescribed medicines. 
Around 35% of those aged 85 years and above are receiving more than ten medicines.  
 
<INSERT FIGURE 2 HERE> 
 
Two key Scottish Government policy documents led to scrutiny of medicines related issues in 
older people. The Reshaping Care for Older People: A Programme for Change 2011-2021 
(2020 vision) aims to improve the quality and outcomes of current models of care for older 
people [54]. The 2010 Healthcare Quality Strategy recommends more team working and that 
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optimal use of skills of different healthcare professionals should be considered in order to 
address future workforce challenges and to enable delivery of clinical care in a sustainable 
way [55].  
 
With publication of these strategic documents, and a significant drive from clinicians, local 
guidelines to promote appropriate polypharmacy started to develop from 2010 onwards. This 
culminated in the publication in 2012 of national guidance on managing inappropriate 
polypharmacy [56] which was updated in 2015 and upgraded to be available across a variety 
of digital platforms [29]. These were developed by a multidisciplinary group of professionals 
from across primary and secondary care, led by pharmacy and medical specialists serving as 
policy makers, with input from other members of the multidisciplinary team and patients. 
Evidence-based approaches are key hallmarks of these guidelines.  
 
The definitions of appropriate and inappropriate polypharmacy were expanded from those of 
Patterson et al [15-17]. Appropriate polypharmacy is present when: all medicines are 
prescribed for the purpose of achieving specific therapeutic objectives that have been agreed 
with the patient; therapeutic objectives are actually being achieved or there is a reasonable 
chance they will be achieved in the future; medicines have been optimised to minimise the 
risk of ADRs; and the patient is motivated and able to take all medicines as intended. 
Inappropriate polypharmacy is present when: one or more medicines are prescribed that are 
not (or no longer) needed, either because there is no evidence-based indication, the indication 
has expired or the dose is unnecessarily high; one or more medicines fail to achieve the 
therapeutic objectives they are intended to achieve; one, or the combination of several 
medicines, cause unacceptable ADRs, or put the patient at an unacceptably high risk of such 
ADRs; and the patient is not willing or able to take one or more medicines as intended. 
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In the absence of definitive evidence on which patients are most likely to benefit from a 
holistic review of their medicines, the guidelines suggest prioritising two groups of patients. 
The first group includes those in care homes aged 50 years and over, regardless of the 
number of medicines prescribed. The second is all those aged 75 years (progressing to 65-74 
years as resources allow) prescribed ten or more medicines, one of which is considered a high 
risk medicine (e.g. benzodiazepines, anticholinergics) and with a Scottish Patients at Risk of 
Readmission and Admission (SPARRA) score in the range of 40 to 60%. SPARRA estimates 
the risk of emergency admission in the next 12 months for approximately 3.6 million 
individuals aged 16 years and over [57]. These patients can be identified from primary care 
medical practice databases. 
 
While not intending to be exhaustive, the guidelines highlight high risk medicines in older 
people, providing an amalgamation of existing collections of explicit medication assessment 
tools [18] Emphasis is also placed on identifying high impact medicines which ideally should 
be continued or started. Furthermore, practitioners are encouraged to consider the likely 
impact of medicines on the individual patient. Being aware of the number needed to treat 
(NNT) of different therapies for the same disorder can help to inform rational and patient-
centred therapy [58]. Drug efficacy information (clinical trial data on intervention, 
comparator, study population, duration, NNT and annual NNT) is presented for the 
management of hypertension, heart failure, cerebrovascular disease, diabetes mellitus and 
osteoporosis.  
 
The 2015 guidance builds on and refines the medicines review process described in the 2012 
guidance. The seven step process provides a standardised structure for the medicines review, 
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with greater focus on patient-centredness and a holistic approach, which considers ‘no 
therapy’ solutions. There is acknowledgement that decision making is complex and should 
take into account multimorbidities, safety, efficacy and acceptability of medicines, the 
patient’s wellbeing, social circumstances and desires. Each of the seven steps focus on a 
different aspect which, in conjunction, are designed to lead to a patient specific and holistic 
review of medicines. Importantly the seven step process commences and ends with focus on 
patient specific clinical outcomes related to health and wellbeing, as defined by the patient. 
Evidence-based recommendations focus on which medicines to consider stopping and 
starting [59,60], and high risk medicines such as anticholinergics [61,62]. The seven steps are 
summarised in Table 4.  
 
<INSERT Table 4 HERE> 
An Australian group addressing polypharmacy through a programme of “deprescribing” 
present a five step process which considers similar aspects [63]. 
  
The polypharmacy guidance has been disseminated widely to policy makers, health 
professionals and patient groups in Scotland. Given that general practitioners are responsible 
for the majority of prescribing in Scotland, the delivery of the strategy was designed initially 
around primary care. It was therefore a major milestone when, in 2013, polypharmacy 
medicines review, as part of anticipatory care reviews, was added to the general practitioners’ 
contract. This requires a quota of reviews to take place, where possible with the support of a 
pharmacist [64]. It is, however, recognised that other health professionals (predominantly 
nurses) with patient contact and medicines related training have responsibilities around 
promoting appropriate polypharmacy in older people. Notably, nurse and pharmacist 
independent prescribers may, within their competence, prescribe the same range of medicines 
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as physicians [65]. In 2013, the Scottish Government published its strategy for 
pharmaceutical care, ‘Prescription for Excellence’, which describes an integrated, 
multidisciplinary approach to optimising pharmaceutical care [66]. This strategy articulates 
the role of pharmacist independent prescribers in patient management and that by 2023, all 
patient facing pharmacists will be independent prescribers managing caseloads of patients, 
which will provide greater opportunity for promoting appropriate polypharmacy.  
 
The polypharmacy guidance is also being integrated within undergraduate and postgraduate 
education and training programmes in Scotland, to embed and normalise the seven step 
process. Recently a mobile phone app has been developed to enable easy access to the 
guidance. The processes of medicines prescribing and review will continue to evolve and 
adapt over time as the health service in Scotland adapts to care for a changing population. 
 
4. Other SIMPATHY work packages 
4.1 Case studies 
SIMPATHY involves several inter-related work packages. One of the foundational work 
packages is a series of nine case studies conducted in eight EU countries (Germany, Greece, 
Italy, Poland, Portugal, Spain (Catalonia), Sweden, and the UK (Scotland and Northern 
Ireland)). A case study investigation is described as a ‘wrapper for different methods’ [67], or 
a means with which ‘to explain present circumstances…[through]…in-depth description of 
social phenomenon’ [68]. The aim of conducting the case studies is to understand what types 
of polypharmacy programmes have been developed, mapping out the structures, processes, 
and outcomes of policies and practices at the institutional, local, regional and national levels. 
These case studies informs for the development of change management tools that will be 
developed by SIMPATHY. The case studies in each country consist of three phases of: a desk 
review of published and grey literature describing the legislation, policies, and procedures 
18 
 
 
that support the programme; one-to-one key informant interviews with policy makers, 
managers, and clinicians to assess the change management and leadership strategies involved 
in implementing the programme; and focus group discussions with health care providers, and 
policy makers.  
 
4.2 Change management 
Securing change in large healthcare systems is a major challenge. There is a natural inertia 
which must be overcome by conceiving, implementing and coordinating an accessible, 
achievable change management programme. The first test for any would be implementer is to 
ask, ‘do compelling reasons for change exist?’ In several countries, there is evidence that the 
necessary impetus is present to drive ongoing transition towards substantial health reforms 
focusing on appropriate polypharmacy. The catalytic trigger is the burden imposed by the 
epidemics of non-communicable diseases (NCDs) including cardiovascular, respiratory, 
metabolic, rheumatologic and neurologic disorders, and cancers, and inevitable 
multimorbidities [69]. Two additional key factors are accelerating changes in healthcare: the 
need for generating efficiencies which allow further investment in innovation without 
increasing overall health costs; and, the paradigm change in the understanding of the 
underlying mechanisms of these NCDs and the focus on strategic partnerships involving all 
stakeholders associated with patient-centred care [70].  
 
Managing inappropriate polypharmacy and promoting appropriate polypharmacy is complex 
with multiple aspects of healthcare practice and delivery of care. To understand fully the 
current situation in the EU, mixed-methods approach is being used in SIMPATHY, drawing 
on methodologies, methods and theories from multiple disciplines applied by a 
multidisciplinary research team.  
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Kotter’s eight step process for leading change [71] involves the following steps: create a 
sense of urgency; build guiding coalitions; form strategic vision and initiatives; enlist 
volunteers; enable action by removing barriers; generate short terms wins; sustain 
acceleration; and, thereby institute sustainable change. There are several key organisational 
features which are more likely to lead to adaptive change. These include organisations which 
are open to exploring different methods of achieving a task making iterative changes where 
and when necessary [72], adaptive leadership where strategic behaviours are encouraged or if 
individuals feel safe to take risks or not [73], leading cross-functional teams [74]. An outline 
change management programme, based upon these principles, is set out in Table 5. 
 
This mixed-method, multi-pronged approach will provide a rich assessment of current 
polypharmacy management in Europe. It will be the foundation for future change 
management tools which enable other countries to address the growing concern of 
inappropriate polypharmacy. These tools will be adaptable and applicable to a range of 
healthcare settings, enabling local policy makers and clinicians to create programmes that 
reflect their specific patient populations, cultures, and health care systems.  
 
Innovations in the management of polypharmacy are key themes within the European Union 
Framework Programme for Research and Innovation. In addition to SIMPATHY, there are 
several high profile projects. PRIMA-EDS (Polypharmacy in chronic diseases: Reduction of 
Inappropriate Medication and Adverse drug events in elderly populations by electronic 
Decision Support) aims to first gather current best evidence regarding drug treatment of 
multimorbid elderly patients then develop an electronic decision support tool (eDS-tool) to 
aid physicians and patients to make use of current best evidence when coming to a shared 
decision regarding multiple drug treatment of the most common chronic diseases. The final 
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stage is a randomized controlled trial with hospital admission rate and mortality as primary 
clinical outcomes [75]. OPERAM (OPtimising thERapy to prevent Avoidable hospital 
admissions in the Multimorbid elderly) aims to test the effect of a software-based 
intervention in 1,900 co-morbid elderly patients [76]. SENATOR (Development and clinical 
trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug 
Therapy in Older peRsons) aims to develop a highly-powered and efficient software engine 
(SENATOR). It is hoped that SENATOR will be capable of individually screening the 
clinical status and pharmacological and non-pharmacological therapy of older people with 
multi-morbidity in order to define optimal drug therapy [77]. 
 
5. Expert Opinion  
Each succeeding generation of healthcare providers faces new challenges. While there have 
been remarkable developments in pharmacotherapy, coupled with the plethora of evidence-
based clinical guidelines to support the management of single conditions, we now need the 
clinical and management courage to recognise that these approaches address poorly the needs 
of older people who constitute an ever increasing proportion of the population [9].  
 
The challenges are on many levels, primarily clinical, organisational and political, and any 
workable, sustainable solution will need to address each and all of these. To be effective, safe 
and efficient, any programme that attempts to deal with the complexities of prescribing and 
promoting appropriate polypharmacy in this population must be patient-centred, clinically 
robust, multidisciplinary and designed to fit into the healthcare system in which it is 
delivered.  
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Within the clinical domain, it is essential to ensure that guidance is evidence-based but also 
pragmatic. This requires consideration of where strong evidence exists for a specific 
treatment strategy but also highlighting where evidence is lacking or where, due to a lack of 
applicability and generalisability, it would be ineffective or potentially harmful to extrapolate 
recommendations to multimorbid older people. Guidelines for this population need to be 
based on a holistic approach to prescribing, with subsequent, regular medicines review. This 
must be based on the individual needs, goals and desires of the individual patient, considered 
alongside the efficacy or otherwise of the medicines regimen. 
 
Clinical consensus and workable guidance are not, however, the only criteria for success. To 
be considered truly successful, any programme needs to be judged by those commissioning 
healthcare as a cost effective, as well as clinically effective, approach to increasing quality of 
care. It is relatively simple to outline the complexities, issues and gaps in knowledge around 
prescribing for frail older people and the consequences of ever increasing burden of 
medicines. For commissioners, however, these messages may be lost amidst the clamour of 
many competing and equally worthy demands. The managers of these polypharmacy 
programmes need to be able to communicate the clinical sense of urgency at the highest 
levels to demand and drive sustainable change. This requires a very clear strategy which 
outlines a workable, deliverable and cost-effective solution acceptable to clinicians and 
patients. 
 
SIMPATHY, with its focus on existing guidance documents promoting appropriate 
polypharmacy aims to identify best practice and collaborative learning from EU countries to 
stimulate further workable innovation, with lessons which could be implemented globally 
[22]. Work completed to date suggests that to succeed and importantly be sustained, any 
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programme would be best developed and implemented within a framework of a clear change 
management strategy. Without this comprehensive, co-ordinated strategy it is unlikely that 
any programme can be delivered consistently, equitably and be sustained across a population, 
irrespective of clarity and robustness of the clinical aspects of any guidance.  
 
The Scottish experience is perhaps the furthest developed in the sense of having robust and 
evidence-driven guidance, coupled with a clear delivery strategy [29]. There was early 
recognition of a need for promoting appropriate polypharmacy in older, multimorbid people 
to be part of standard practice. The change management strategy aligned to Kotter’s eight 
step process [71] encourages engagement of senior management at the government level, as 
well as practising members of the multidisciplinary team and patients, at a very early stage. 
Initial pilot work and implementation on the national scale involved monitoring and 
providing feedback of estimations of clinical and economic impact. Creating a sense of 
urgency and vision for such a strategy to help address the political and economic factors has 
been an iterative process that is reviewed continually over time. Acceptance of the 
programme by patients is powerful in political terms. These are essential elements in 
successful delivery and sustainability.  
 
Considerable work was undertaken to ensure the polypharmacy guideline was approved and 
hosted by the Scottish Intercollegiate Guidelines Network (SIGN), the main centre for 
national disease specific guidelines [78]. The polypharmacy guidance is now the most 
downloaded guidance on the SIGN website. It is now imperative that robust and rigorous 
evaluative research data are gathered demonstrate the impact of the guidance in terms of 
clinical, humanistic and economic outcomes. In conclusion, there is a need to manage 
inappropriate polypharmacy and promote appropriate polypharmacy in an increasingly 
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complex, multimorbid ageing population. In clinical terms this will require clinicians across 
multiple healthcare disciplines in each country to agree on guidance that will begin to take 
account of adults whose prescribing needs require a much more holistic approach. The 
evidence demonstrates clearly that the time has come to reject the reliance on single disease 
state focused guidelines when treating multimorbid patients. In future, plans must be 
developed and implemented within a framework of a clear change management strategy and 
be coupled with rigorous and robust evaluation.   
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Table 1 – Summary of the grey literature search.$ number of the keywords has been adjusted to the local language, # number of search results lower 
than the target due to some combination of keywords retrieving <10 results 
Country No. of keyword 
combinations used 
for the search (No. 
of individual 
keywords from 
Group 1 & 2) 
No. of search 
results  
Excluded after screening: No. of full text 
items assessed 
No. of 
identified 
guidance 
documents 
fulfilling all 
criteria 
For not dealing with 
polypharmacy 
management in 
older people  
For other 
reasons 
Germany 24 (6 * 4) 240 89 102 49 1 
Greece 24 (6 * 4) 179
# 166 13 0 0 
Italy 12$ (4 * 3) 100
# 46 47 7 0 
The Netherlands 4$ (2 * 2) 40 19 20 1 1 
Poland 24 (6 * 4) 233
# 165 55 13 0 
Portugal 24 (6 * 4) 150
# 113 29 8 0 
Sweden 3$ (3 * 1) 30 0 26 4 4 
Spain 8$ (2 * 4) 66
# 2 63 1 0 
Scotland 24 (6 * 4) 240 156 80 4 4 
Northern Ireland 24 (6 * 4) 187
# 21 165 1 0 
Non-country 
specific search 24 (6 * 4) 
240 30 210 0 0 
Total  1705 807 810 88 10 
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An additional 14 guidance documents were identified, as shown in Table 2.  
 
Table 2 – Guidance documents identified through other methods 
Country No. of identified guidance 
documents  
Germany 1 
Greece 0 
Italy 0 
The Netherlands 4 
Poland 0 
Portugal 0 
Sweden 4 
Spain 1 
United Kingdom 4 
Total 14 
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Table 3 – Guidance documents identified with AGREE II scores 
 
Guidance document details Country of 
origin 
Overall 
score 
according 
to 
AGREE 
II 
Regionala läkemedelsrådet i Uppsala-Örebroregionen. 
Behandlingsrekommendationer 2015. 
Läkemedelsbehandling av de mest sjuka äldre. Version 1.2: 
Updated March 2015 [28] 
Sweden 6 
Scottish Government Model of Care Polypharmacy 
Working Group. Polypharmacy Guidance (2nd edition). 
March 2015 [29] 
Scotland 7 
Västerbottens läns landsting. Terapirekommendationer, 
2015 [30] 
Sweden 5 
Västra Götalandsregion. Äldre och läkemedel, 2015 [31] Sweden 4 
Bergert FW, Braun M, Ehrenthal K, et al. 
Recommendations for treating adult and geriatric patients 
on multimedication, 2014 [32] 
Germany 7 
Corrine Zara. Rational drug use. Medication management 
in the complex chronic patient: reconciliation, revision, 
deprescription and adherence, 2014 [33] 
Spain 5 
Ingrid Schubert, Hausärztlicher Leitliniengruppe Hessen 
und DEGAM. Hausärztliche Leitlinie „Multimedikation“, 
2014 [34] 
Germany 5 
Midlöv P, Kragh A. Chapter: Läkemedelsbehandling hos 
äldre. In: Läkemedelsboken. Uppsala: Läkemedelsverket. 
2014 [35] 
Sweden 3 
Verenso. Handreiking Geriatrisch assessment door de 
specialist ouderengeneeskunde. Utrecht: Verenso. 2014 
[36] 
The 
Netherlands 
3 
Duerden M, Avery T, Payne R. Polypharmacy and 
medicines optimisation: Making it safe and sound. The 
King's Fund. November 2013 [37] 
England 6 
Jones E. Polypharmacy: Guidance for Prescribing in Frail 
Adults. NHS Wales. May 2013 [38] 
Wales 5 
Nederlandse Vereniging voor Klinische Geriatrie. Richtlijn 
comprehensive geriatric assessment. Utrecht: Nederlandse 
Vereniging voor Klinische Geriatrie. 2013 [39] 
The 
Netherlands 
5 
Socialstyrelsen. Läkemedelsgenomgångar för äldre 
ordinerade fem eller fler läkemedel. Stockholm: 
Socialstyrelsen. 2013 [40] 
Sweden 5 
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Stockholms läns landsting. Äldre och läkemedel, 2013 [41] Sweden 5 
Nederlands Huisartsen Genootschap. Multidisciplinaire 
richtlijn Polyfarmacie bij ouderen 2012. Utrecht: 
Nederlands Huisartsen Genootschap. 2012 [42] 
The 
Netherlands 
6 
NHS Greater Glasgow & Clyde. Mindful Prescribing 
Strategy – Polypharmacy. NHS. December 2012 [43] 
Scotland 6 
Melander A, Nilsson LG. Olämpliga listan - Koll på 
läkemedel, 2011 [44] 
Sweden 5 
Verenso. Multidisciplinaire richtlijn diabetes bij kwetsbare 
ouderen. Utrecht: Verenso. 2011 [45] 
The 
Netherlands 
7 
Socialstyrelsen. Indikatorer för god läkemedelsterapi hos 
äldre. Stockholm: Socialstyrelsen. 2010 [46] 
Sweden 5 
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Table 4 – An overview of the seven steps process (adapted from 29) 
Domain Steps Process 
Aims 1. Identify 
objectives of drug 
therapy 
Review diagnoses and identify therapeutic 
objectives with respect to management of existing 
health problems and prevention of future health 
problems 
 
Need 2. Identify 
essential drug 
therapy 
Identify essential drugs (not to be stopped without 
specialist advice). These include drugs that have 
essential replacement functions (e.g. levothyroxine) 
and drugs to prevent rapid symptomatic decline (e.g. 
for Parkinson’s disease) 
 
3. Does the patient 
take unnecessary 
drug therapy? 
Identify and review the (continued) need for drugs 
such as those with: temporary indications; higher 
than usual maintenance doses; limited benefit in 
general or the indication they are used for; limited 
benefit in the patient under review  
 
Effectiveness 4. Are therapeutic 
objectives being 
achieved? 
Identify the need for adding/intensifying drug 
therapy in order to achieve therapeutic objectives of: 
symptom control; biochemical/clinical targets; 
preventing disease progression/exacerbation 
 
Safety 5. Does the patient 
have ADR or is at 
risk of ADRs? 
Identify patient safety risks by checking for: drug-
disease interactions; drug-drug interactions; 
robustness of monitoring mechanisms for high-risk 
drugs; risk of accidental overdosing 
  
Identify adverse drug effects by checking for: 
specific symptoms/laboratory markers; cumulative 
adverse drug effects; drugs that may be used to treat 
ADRs caused by other drugs 
 
Cost 
effectiveness 
6. Is drug therapy 
cost-effective? 
Identify unnecessarily costly drug therapy by 
considering more cost-effective alternatives (but 
balance against effectiveness, safety, convenience) 
 
Adherence/ 
Patient 
centeredness 
7. Is the patient 
willing and able to 
take drug therapy 
as intended? 
Identify risks to patient non-adherence by 
considering if: the medicine is in a form that the 
patient can take; the dosing schedule is convenient; 
the patient is able to take medicines as intended 
 
Ensure drug therapy changes are tailored to patient 
preferences by: discussing with the 
patient/carer/welfare proxy therapeutic objectives 
and treatment priorities; deciding with the 
patient/carer/welfare proxies what medicines have 
an effect of sufficient magnitude to consider 
continuation or discontinuation 
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Table 5 – Polypharmacy change management programme 
1. Establish a sense of urgency 
Communicating to stakeholders the need to change current ways of reviewing medicines 
to benefit patient care. Examining other projects that are developing and whether they 
pose a threat to the development of the framework.  
 
2. Form a powerful guiding coalition 
Facilitate the assembly of a project group including in each country comprising both 
primary and secondary care and collaborative leads locally and nationally for long term 
health conditions. These groups should then engage with the work of those responsible 
for the delivery of healthcare and public health both locally and nationally.  
 
3. Create a vision 
The vision describes ‘how we want the story of polypharmacy in each country to turn 
out’. It should be compelling in the way it addresses the concerns and issues of different 
stakeholders. 
 
4. Communicating the vision  
This is the heart of the change management process and involves hard work on the part 
of the teams in each country to show tenacity and persistence in winning hearts and 
minds to the need for change and how it can be realised in practical steps. 
 
5. Empowering others to act on the vision 
Visions succeed when the means of achieving them cascades from the top level to the 
lowest level of delivery. Understand the obstacles to change at each level so that they 
take ownership of problems and solutions. Provide feedback and facilitate adaptation of 
the protocol e.g. link with anticipatory care plans. 
 
 
 
